Chairman of the Board
Mr. Carlton has substantial industry, entrepreneurial and high-growth public- company execution expertise. He has an extensive, demonstrated record of success in launching new products into global medical and aesthetic markets. Most recently serving as Chief Executive Officer of Quanta Aesthetic Lasers USA, LLC., Mr. Carlton was recognized by Aesthetics Everything®, the largest social network in aesthetics, as one of the “Top 10 CEO’s and Presidents in 2016”.
Previously, Mr. Carlton was President, NA for Syneron-Candela, one of the largest companies in the aesthetic energy-based device market. Mr. Carlton has significant commercialization experience, and over the past 25 years, has served as Vice President and Global General Manager – Interventional Oncology at Covidien, LTD; was CEO of NASDAQ-listed SRI Surgical; President of Dräger Medical; and served in positions of progressively greater leadership responsibility over eleven years with GE Marquette Medical Systems.
Mr. Carlton holds a BS in Industrial Engineering (With Honors), a Graduate Diploma in Management, and an MBA. He is a graduate of the GE Management Development Institute-Crotonville, and the Program on Negotiation at Harvard Law School.
Mr. Carlton and his wife, Hala, have been married for over 30 years and reside in Clearwater, Florida. They have three children. Together, they focus on family vacations, music, and outdoor activities.
Mr. Barbera has over 35 years' of experience in developing, operating and investing in startup companies. He has extensive experience in fundraising and secured over $55M in private equity for a company he previously founded.
Mr. Barbera has played key leadership roles in acquisitions, capital formation, business development, and the operation of numerous startup companies. Mr. Barbera has consistently built organizations with the solid foundation required to sustain rapid growth. His experience demonstrates a style of leadership that integrates integrity and compliance with success.
Accure Acne, Inc. is the third laser-based startup by Mr. Barbera. In addition to lasers, he has a demonstrated track record of success in diverse industries. Mr. Barbera started his career as a Senior Consultant with Peat|Marwick|Mitchell.
Mr. Barbera served on active duty in the United States Navy from 1972 to 1976. He received his Bachelor of Business Administration degree with a major in accounting from the University of Massachusetts – Amherst, became a Certified Public Accountant and has previously been a member of the National and Colorado Societies of CPAs.
Mr. Barbera is active in the community, with his church, and is a member of the World Presidents' Organization. He resides in Greenwood Village, CO with his wife of 40 years, Andrea. Together, they have one daughter, Nicole.
Craig A. Drill is the Managing Member of, and has been the sole Portfolio Manager of, Craig Drill Capital, L.P. since inception in 1988. From 1973 through 1987, Mr. Drill was employed by The First Boston Corporation as Vice President of the Equity Department, National Research Coordinator, and a senior member of the firm’s Investment Policy Committee. From 1969 to 1973, Mr. Drill was employed by Burnham and Company as National Institutional Sales Manager and a Corporate Vice President, and he served on the firm’s Investment Policy, Buying, Pricing and Marketing Committees.
Mr. Drill received his MBA from Harvard Business School in 1969 and a BA from Princeton University in 1964. Mr. Drill served as an officer in the United States Navy from 1964 until 1967.
Mr. Hofvander has an extensive background in hi-tech entrepreneurial companies including more than 20 years with companies founded on laser-based technologies. Mr. Hofvander is the driving force behind many of the unique technical solutions of the Accure device. He also leads Accure’s integrated clinical and technical development, coordinating with clinical and manufacturing partners, and is responsible for Accure’s IP portfolio.
Mr. Hofvander was formerly the CEO of Zolo Technologies, Inc., a venture-capital-backed startup that successfully commercialized laser systems for telecom, aerospace, and ultra-harsh industrial environments. Prior to Zolo, Mr. Hofvander was the GM of Melles Griot Electro-Optics, a company that develops solid-state laser systems. In his career, Mr. Hofvander has raised in excess of $25M of venture funding.
Mr. Hofvander graduated at the top of his class at the Lund Institute of Technology, Sweden, with a BSc and MSc in EE/CS. He was a Fulbright scholar at Columbia University and holds numerous patents.
Vladimir Paul-Blanc has over 16 years’ experience in medical devices, with his core expertise in namely the energy-based devices categories of dermatology, plastic surgery, and medical aesthetics. He has a diversified background in various leadership roles across key functional areas, including clinical education and development, product development and commercialization, both domestic and international business unit leadership roles, business development, and global executive appointments.
Most recently, Mr. Paul-Blanc served as President and General Manager of Thermi, where he led the post-acquisition integration, stabilization, and ultimate carve-out of the business unit to a strategic partner in the medical aesthetics and regenerative medicine space. Prior to Thermi, Mr. Paul-Blanc served thirteen years at Solta Medical in diversified and expanded leadership roles, culminating with his appointment as General Manager. He has presented at numerous scientific meetings around the world and has consulted and advised medical device corporations, financial institutions, and medical societies and organizations.
Mr. Paul-Blanc holds a B.A. in Biology from Brown University and is married with one child. They currently reside in the Providence, RI area and enjoy family time, music and cherish opportunities to experience various cultures through travel and the arts.
Karl Nicholls has over 20 years’ experience in the Medical Device and Biotech Industries; from large global companies, such as Covidien, to early stage companies, such as Biodesix and Accure Acne. Mr. Nicholls is a qualified accountant with a depth and breadth of experience across the entire P&L, from sales and marketing, manufacturing and distribution to research and development. Mr. Nicholls has successfully overseen all financial aspects of an innovative fast-growing technology-based division that recorded double digit revenue growth for 16 straight quarters; a fivefold expansion of the sales team and significant increases in R&D investment. Mr. Nicholls has sat on several portfolio management teams, technology and product development teams and global leadership teams.
Mr. Nicholls’ experience in these roles has given him a unique ability to think both tactically and strategically; particularly in following a product from concept to successful commercialization.
Mr. Nicholls is married, has 4 children and lives in Boulder, CO.
Dr. Ray Sierra was previously Chief Technology Officer of Cynosure, Inc. Dr. Sierra has authored or co-authored more than thirty refereed publications and conference presentations, and three book chapters. He is also the inventor or co-inventor of over thirty U.S. and international patents related to laser design, the use of lasers in medicine, and the measurement of cholesterol.
As a Senior Scientist starting in 1986 at Candela Corp. Dr. Sierra began his long career designing lasers for medical applications. While at Candela he worked on a number of lasers for the treatment of vascular malformations, biliary stones, glaucoma, endarterectomy, tattoos, and pigmented lesions. In 1991 he became Director of Laser Technology and led all the activities of Candela’s Laser Technology Division including both the laser development as well as the clinical application of the lasers. From 1995 to 1997 at CeramOptec Dr. Sierra continued the development of medical lasers and their applications introducing diode lasers for urology, ophthalmology.
Dr. Sierra joined Cynosure Inc. in 1997 as its Chief Technology Officer. In his more than twenty years with Cynosure he oversaw the development and introduction of numerous lasers including pulse dye lasers for the treatment of vascular malformations, a line of solid-state alexandrite lasers Nd:YAG lasers and diode lasers for hair removal, ablative Er:YAG lasers for skin rejuvenation, and short pulse nanosecond lasers, as well as the first commercial picosecond lasers for the treatment of tattoos, pigmentation, and facial rejuvenation. Additionally, he was involved with the introduction of lasers for the treatment of unwanted fat and body contouring and invasive as well as non-invasive lasers and laser treatments have for liposuction, fat reduction, long term cellulite improvement, and skin tightening. This broad line of products allowed the company to grow from about $25M annual sales to ~$340M over his tenure.
Dr. Sierra holds a bachelor’s degree from Rensselaer Polytechnic Institute (1971), a master’s degree from the University of R.I. (1973), and a PhD from the University of Texas at Dallas (1978), all in Physics. Following graduation from the University of Texas-Dallas Dr. Sierra served as a Postdoctoral Fellow at the University of Missouri-Rolla and from 1980 to 1984 he was a Staff Member at Los Alamos National Lab.
Dr. Anderson is objectively the most influential scientist in the field of energy-based devices used in aesthetics. Dr. Anderson graduated from MIT and then received his medical degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty where he is now a Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine, and adjunct Professor of Health Sciences and Technology at Massachusetts Institute of Technology (MIT).
Dr. Anderson has contributed significant advancements to the effort to cure acne. This includes significant pre-clinical, clinical and product development efforts which built upon his initial conceptualization and co-development of the concept of microscopic target-selective laser therapy, now in widespread use for removal of pigmented lesions, tattoos and hair, along with treatment of port wine stains, birthmarks, vocal cords, kidney stones, glaucoma, heart disease, photodynamic therapy for cancer and acne, and optical diagnostics. His research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions.
Dr. Anderson has been awarded over 60 national and international patents and has co-authored over 425 scientific books and papers. He invented or co-invented fractional laser skin treatments, the confocal laser scanning microscope for human skin imaging and the development of lasers for lithotripsy, cardiovascular and eye diseases. ResearchGate indicates that his 330 publications have been cited by other researchers greater than 21,800 times. Dr. Anderson is considered the father of the aesthetics industry. Dr. Anderson is a 2020 Inductee to the National Inventor’s Hall of Fame.
Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in medical care. These include the entire industry of laser hair removal. His invention of selective cryolipolysis, which uses cold cycles to preferentially remove adipose tissue, led to the formation of Zeltiq Aesthetics, Inc. (ZLTQ), a global aesthetics company which was acquired by Allergan in 2017 for approximately $2.4 billion in cash.
Dr. Anderson has developed treatments for birthmarks, microvascular and pigmented lesions, and tattoo removal. He has also contributed to treatment for vocal cords, kidney stones, glaucoma, heart disease, photodynamic therapy for cancer and acne, and optical diagnostics. Dr. Anderson's research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions.
In addition to research at the Wellman Center, he practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT. Dr. Anderson is married to renowned Clinical Researcher Fernanda Sakamoto, MD, PhD. They have two children and make their home near Cambridge, MA.
Dr. Tanghetti has published influential papers on the treatment of acne vulgaris through a variety of methods, including lasers and light-based devices, topicals and drug therapies. In addition to his academic credentials, Dr. Tanghetti brings valuable insight of a private practice dermatologist. He received early admission to UCLA School of Medicine after only three years of undergraduate studies. Upon completing his medical studies and a 1-year pathology fellowship, Dr. Tanghetti graduated first in his class at UCLA and received the Dean Warren Medal for Academic Excellence. After finishing residencies in Internal Medicine at Stanford University and Dermatology at Harvard School of Medicine, he completed a Photomedicine fellowship at the Massachusetts General Hospital. Dr. Tanghetti is a board-certified dermatologist and a Fellow in the AAD and ASLMS. His work has been published in journals such as Lasers in Surgery and Medicine, Journal of Dermatologic Surgery, the Journal of Cosmetic and Laser Therapy, and Cutis, and has presented data at the meetings of the American Society for Laser Medicine and Surgery and the American Academy of dermatology as well as Laser Innsbruck. Dr. Tanghetti is an internationally recognized speaker and consultant.
Dr.Geronemus is Director of the Laser and Skin Surgery Center of New York, is a graduate of Harvard University and University of Miami School of Medicine, and the New York University Medical Center where he was the chief resident and fellowship-trained in Mohs Micrographic Surgery and Cutaneous Oncology. He is a Clinical Professor of Dermatology at New York University Medical Center where he founded its laser program and served nine years as chief of dermatologic and laser surgery. He is past president of the ASDS and ASLMS. Dr. Geronemus is the Chairman of the Board of the New York Stem Cell Foundation. ASLMS awarded Dr. Geronemus the Ellet Drake award for outstanding contributions to laser medicine and the Leon Goldman award for excellence in clinical laser research. ASDS awarded him the Samuel J. Stegman award for distinguished service and the University of Miami School of Medicine has elected him into their Hall of Fame. He has published over 350 medical articles, chapters and books.
Dr. Sakamoto is the primary author of the pivotal paper that led to the conclusion that Selective Photothermolysis of sebaceous glands was feasible. This study, which utilized the Jefferson National Accelerator superconducting Free Electron Laser, measured Selective Photothermolysis in the spectrum between 200nm to 3000nm. It was found that optical pulses at “…~1720nm, ~100-125 millisecond pulses showed evidence of selective thermal damage to sebaceous glands…Epidermis was undamaged in all samples.” Dr. Sakamoto is co-author of a chapter entitled, “Laser and Light Therapy for Acne Vulgaris”, published in the 2014 textbook “Laser and Light Source Treatments for the Skin”, is author of over 48 medical articles and is Assistant Professor in Dermatology at Harvard Medical School. She is a fellow of the AAD, fellow of the ASLMS, a member of the Société Française de Dermatologie; of the Brazilian Society of Dermatology, of the Brazilian Society of Dermatological Surgery, of the Brazilian Group of Melanoma and of the International Society of Dermoscopy. Dr. Sakamoto is on the editorial board of Journal of Investigative Dermatology and has served on the ASLMS Education and International Committees.
Dr. Ross is the director of the Scripps Clinic (San Diego, CA) Laser and Cosmetic Dermatology Center, a frequent lecturer at national and international meetings on cutaneous laser medicine, and a board-certified dermatologist. Dr. Ross was President of ASLMS and elected to the board of the ASDS. Dr. Ross serves on the editorial board of two major dermatologic journals. Dr. Ross graduated summa cum laude with a B.S. in physics from Mississippi State University. He obtained his medical degree from the Tulane University School of Medicine where he was a junior year inductee into Alpha Omega Alpha. In 1992, Dr. Ross completed a three-year dermatology residency at the National Naval Medical Center in Bethesda. In 1994 he was the first Navy-sponsored fellow in Photomedicine and Lasers at Massachusetts General Hospital. His special interests are laser skin resurfacing, fractional laser applications, photodynamic therapy, non-ablative skin remodeling, laser treatment of leg veins, laser treatment of acne, and laser hair reduction in dark skinned patients. He is the author of over 125 articles and seven book chapters.
Dr. Ray Jalian, Board Certified Dermatologist by the American Board of Dermatology, brings to the practice some impressive credentials. With a Dermatology Fellowship at Harvard/Mass General following his medical training at UCLA and Cedars Sinai, Dr. Jalian has acquired particular skills with fractional laser. His laser specialties include acne scarring, trauma, surgical scars, and photo damaged. Dr. Jalian is the 2020 Honorary Award Recipient of the Dr. Horace Furumoto Young Investigator Award from ASLMS, as well as a 2018 ASLMS Presidential Citation.
Dr. Jalian graduated phi beta kappa from the University of California, Los Angeles with a bachelor of science degree in microbiology, immunology, and molecular genetics. He attended medical school at the David Geffen School of Medicine at UCLA where he graduated Alpha Omega Alpha.
He served as chief resident at UCLA followed by a clinical fellowship at the Wellman Center of Photomedicine at Massachusetts General Hospital. Research interests include pathogenesis and treatment of acne and vascular malformations. Prior to joining the practice, Dr. Jalian was on staff at UCLA Department of Medicine in Santa Monica.
Prof. Dr. med. Prof. honoraire Dr. h.c. Christos Zouboulis is Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center and Founding Professor of Dermatology and Venereology at the Theodor Fontane Medical University of Brandenburg, Germany. He currently serves as President of the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Honorary President of the European Society of Preventive, Regenerative and Anti-Aging Medicine (ESAAM) and Board member of the European Academy of Dermatology and Venereology (EADV) and the International Society on Behçet’s Disease. Prof. Zouboulis is currently the Editor of the EADV News, Co-Editor of Rejuvenation Research and serves in the Editorial Boards of several leading international scientific journals. He was elected Prof. honoraire of the University of Franche-Comté, Besançon, France, Dr. h.c. of the National Kapodistria University of Athens and Visiting Professor of the Jiao Tong University of Shanghai, China. He is an honorary member of the French, the Hungarian, the Maltese, and the Lithuanian Dermatological Societies. Prof. Zouboulis has an extensive publication record on skin endocrinology, the pilosebaceous unit and its diseases, skin stem cells, molecular aging, cryosurgery, and rare skin diseases. He has received numerous awards, including the Oskar Gans Prize, the EADV Research Fellowship, the Felix Wankel Animal Protection Research Prize, the Paul Gerson Unna Prize and the Springer Prize for Dermatology. His Departments have been decorated with the title "Germany land of ideas - 2009 place of excellence" for the work on skin stem cells.
Dr. James J. Leyden, emeritus professor of Dermatology at the University of Pennsylvania, has been a consultant to the Food and Drug Administration, the Federal Trade Commission and to drug regulation agencies in England, Germany, and Austria. A past member of the American Academy of Dermatology Board of Directors and former chairman of the Board of the Dermatology Foundation, his research has focused on a variety of clinical problems, including bacterial and fungal infections, acne, aging and photoaging, and developing methodologies for in-vivo evaluation of anti-microbial effects. He has studied mechanisms of inflammation in acne, bacterial taxonomy and bacterial production of body odors. Dr. Leyden has also been instrumental in developing, testing and commercializing Retin-A, Accutane, Bactroban, Nizoral, Cleocin, Benzamycin, Benzaclin, and Minocin. He is internationally recognized for his contributions to dermatology, particularly to the understanding of the pathophysiology, diagnosis, and treatment of acne and rosacea.